Royalty Pharma PLC $RPRX Shares Sold by Aurora Investment Counsel

Aurora Investment Counsel lowered its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 32.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,415 shares of the biopharmaceutical company’s stock after selling 16,861 shares during the period. Aurora Investment Counsel’s holdings in Royalty Pharma were worth $1,699,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Morgan Stanley boosted its stake in shares of Royalty Pharma by 25.2% during the 4th quarter. Morgan Stanley now owns 55,274,069 shares of the biopharmaceutical company’s stock worth $2,135,790,000 after acquiring an additional 11,110,115 shares in the last quarter. Capital International Investors grew its holdings in Royalty Pharma by 14.3% in the fourth quarter. Capital International Investors now owns 31,104,309 shares of the biopharmaceutical company’s stock valued at $1,201,870,000 after purchasing an additional 3,891,615 shares during the last quarter. Norges Bank purchased a new position in shares of Royalty Pharma in the fourth quarter valued at $131,923,000. Qube Research & Technologies Ltd increased its position in shares of Royalty Pharma by 737.3% in the third quarter. Qube Research & Technologies Ltd now owns 2,481,771 shares of the biopharmaceutical company’s stock valued at $87,557,000 after buying an additional 2,185,366 shares in the last quarter. Finally, Millennium Management LLC raised its stake in shares of Royalty Pharma by 379.2% during the 3rd quarter. Millennium Management LLC now owns 2,235,133 shares of the biopharmaceutical company’s stock worth $78,855,000 after buying an additional 1,768,702 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RPRX has been the topic of several recent research reports. Citigroup boosted their price objective on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. UBS Group lifted their target price on shares of Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st. TD Cowen upped their price target on shares of Royalty Pharma from $50.00 to $65.00 and gave the company a “buy” rating in a report on Monday, July 13th. Finally, Morgan Stanley increased their price target on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $56.57.

Insider Transactions at Royalty Pharma

In other Royalty Pharma news, Director Gregory Norden sold 3,045 shares of the business’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.00, for a total transaction of $161,385.00. Following the completion of the sale, the director owned 191,803 shares of the company’s stock, valued at approximately $10,165,559. The trade was a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 64,399 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $53.98, for a total value of $3,476,258.02. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 427,800 shares of company stock valued at $23,333,723. Corporate insiders own 18.84% of the company’s stock.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $58.18 on Friday. Royalty Pharma PLC has a 1 year low of $34.08 and a 1 year high of $59.44. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. The firm has a 50 day moving average price of $55.01 and a 200 day moving average price of $48.52. The company has a market cap of $33.50 billion, a price-to-earnings ratio of 39.58, a PEG ratio of 10.30 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The company had revenue of $630.58 million for the quarter, compared to the consensus estimate of $881.69 million. Sell-side analysts predict that Royalty Pharma PLC will post 5.18 earnings per share for the current year.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.